Operational implementation of prospective genotyping for personalized medicine

The design of the vanderbilt PREDICT project

J. M. Pulley, J. C. Denny, J. F. Peterson, G. R. Bernard, C. L. Vnencak-Jones, A. H. Ramirez, J. T. Delaney, E. Bowton, K. Brothers, K. Johnson, D. C. Crawford, J. Schildcrout, D. R. Masys, H. H. Dilks, R. A. Wilke, E. W. Clayton, E. Shultz, Michael Laposata, J. McPherson, J. N. Jirjis & 1 others D. M. Roden

Research output: Contribution to journalArticle

230 Citations (Scopus)

Abstract

The promise of "personalized medicine" guided by an understanding of each individual's genome has been fostered by increasingly powerful and economical methods to acquire clinically relevant information. We describe the operational implementation of prospective genotyping linked to an advanced clinical decision-support system to guide individualized health care in a large academic health center. This approach to personalized medicine entails engagement between patient and health-care provider, identification of relevant genetic variations for implementation, assay reliability, point-of-care decision support, and necessary institutional investments. In one year, approximately 3,000 patients, most of whom were scheduled for cardiac catheterization, were genotyped on a multiplexed platform that included genotyping for CYP2C19 variants that modulate response to the widely used antiplatelet drug clopidogrel. These data are deposited into the electronic medical record (EMR), and point-of-care decision support is deployed when clopidogrel is prescribed for those with variant genotypes. The establishment of programs such as this is a first step toward implementing and evaluating strategies for personalized medicine.

Original languageEnglish (US)
Pages (from-to)87-95
Number of pages9
JournalClinical Pharmacology and Therapeutics
Volume92
Issue number1
DOIs
StatePublished - Jul 2012
Externally publishedYes

Fingerprint

clopidogrel
Precision Medicine
Point-of-Care Systems
Clinical Decision Support Systems
Electronic Health Records
Platelet Aggregation Inhibitors
Cardiac Catheterization
Health Personnel
Patient Care
Genotype
Genome
Delivery of Health Care
Health

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Pulley, J. M., Denny, J. C., Peterson, J. F., Bernard, G. R., Vnencak-Jones, C. L., Ramirez, A. H., ... Roden, D. M. (2012). Operational implementation of prospective genotyping for personalized medicine: The design of the vanderbilt PREDICT project. Clinical Pharmacology and Therapeutics, 92(1), 87-95. https://doi.org/10.1038/clpt.2011.371

Operational implementation of prospective genotyping for personalized medicine : The design of the vanderbilt PREDICT project. / Pulley, J. M.; Denny, J. C.; Peterson, J. F.; Bernard, G. R.; Vnencak-Jones, C. L.; Ramirez, A. H.; Delaney, J. T.; Bowton, E.; Brothers, K.; Johnson, K.; Crawford, D. C.; Schildcrout, J.; Masys, D. R.; Dilks, H. H.; Wilke, R. A.; Clayton, E. W.; Shultz, E.; Laposata, Michael; McPherson, J.; Jirjis, J. N.; Roden, D. M.

In: Clinical Pharmacology and Therapeutics, Vol. 92, No. 1, 07.2012, p. 87-95.

Research output: Contribution to journalArticle

Pulley, JM, Denny, JC, Peterson, JF, Bernard, GR, Vnencak-Jones, CL, Ramirez, AH, Delaney, JT, Bowton, E, Brothers, K, Johnson, K, Crawford, DC, Schildcrout, J, Masys, DR, Dilks, HH, Wilke, RA, Clayton, EW, Shultz, E, Laposata, M, McPherson, J, Jirjis, JN & Roden, DM 2012, 'Operational implementation of prospective genotyping for personalized medicine: The design of the vanderbilt PREDICT project', Clinical Pharmacology and Therapeutics, vol. 92, no. 1, pp. 87-95. https://doi.org/10.1038/clpt.2011.371
Pulley, J. M. ; Denny, J. C. ; Peterson, J. F. ; Bernard, G. R. ; Vnencak-Jones, C. L. ; Ramirez, A. H. ; Delaney, J. T. ; Bowton, E. ; Brothers, K. ; Johnson, K. ; Crawford, D. C. ; Schildcrout, J. ; Masys, D. R. ; Dilks, H. H. ; Wilke, R. A. ; Clayton, E. W. ; Shultz, E. ; Laposata, Michael ; McPherson, J. ; Jirjis, J. N. ; Roden, D. M. / Operational implementation of prospective genotyping for personalized medicine : The design of the vanderbilt PREDICT project. In: Clinical Pharmacology and Therapeutics. 2012 ; Vol. 92, No. 1. pp. 87-95.
@article{0ab35a8a5c6d4105ba9358eec676f7a6,
title = "Operational implementation of prospective genotyping for personalized medicine: The design of the vanderbilt PREDICT project",
abstract = "The promise of {"}personalized medicine{"} guided by an understanding of each individual's genome has been fostered by increasingly powerful and economical methods to acquire clinically relevant information. We describe the operational implementation of prospective genotyping linked to an advanced clinical decision-support system to guide individualized health care in a large academic health center. This approach to personalized medicine entails engagement between patient and health-care provider, identification of relevant genetic variations for implementation, assay reliability, point-of-care decision support, and necessary institutional investments. In one year, approximately 3,000 patients, most of whom were scheduled for cardiac catheterization, were genotyped on a multiplexed platform that included genotyping for CYP2C19 variants that modulate response to the widely used antiplatelet drug clopidogrel. These data are deposited into the electronic medical record (EMR), and point-of-care decision support is deployed when clopidogrel is prescribed for those with variant genotypes. The establishment of programs such as this is a first step toward implementing and evaluating strategies for personalized medicine.",
author = "Pulley, {J. M.} and Denny, {J. C.} and Peterson, {J. F.} and Bernard, {G. R.} and Vnencak-Jones, {C. L.} and Ramirez, {A. H.} and Delaney, {J. T.} and E. Bowton and K. Brothers and K. Johnson and Crawford, {D. C.} and J. Schildcrout and Masys, {D. R.} and Dilks, {H. H.} and Wilke, {R. A.} and Clayton, {E. W.} and E. Shultz and Michael Laposata and J. McPherson and Jirjis, {J. N.} and Roden, {D. M.}",
year = "2012",
month = "7",
doi = "10.1038/clpt.2011.371",
language = "English (US)",
volume = "92",
pages = "87--95",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Operational implementation of prospective genotyping for personalized medicine

T2 - The design of the vanderbilt PREDICT project

AU - Pulley, J. M.

AU - Denny, J. C.

AU - Peterson, J. F.

AU - Bernard, G. R.

AU - Vnencak-Jones, C. L.

AU - Ramirez, A. H.

AU - Delaney, J. T.

AU - Bowton, E.

AU - Brothers, K.

AU - Johnson, K.

AU - Crawford, D. C.

AU - Schildcrout, J.

AU - Masys, D. R.

AU - Dilks, H. H.

AU - Wilke, R. A.

AU - Clayton, E. W.

AU - Shultz, E.

AU - Laposata, Michael

AU - McPherson, J.

AU - Jirjis, J. N.

AU - Roden, D. M.

PY - 2012/7

Y1 - 2012/7

N2 - The promise of "personalized medicine" guided by an understanding of each individual's genome has been fostered by increasingly powerful and economical methods to acquire clinically relevant information. We describe the operational implementation of prospective genotyping linked to an advanced clinical decision-support system to guide individualized health care in a large academic health center. This approach to personalized medicine entails engagement between patient and health-care provider, identification of relevant genetic variations for implementation, assay reliability, point-of-care decision support, and necessary institutional investments. In one year, approximately 3,000 patients, most of whom were scheduled for cardiac catheterization, were genotyped on a multiplexed platform that included genotyping for CYP2C19 variants that modulate response to the widely used antiplatelet drug clopidogrel. These data are deposited into the electronic medical record (EMR), and point-of-care decision support is deployed when clopidogrel is prescribed for those with variant genotypes. The establishment of programs such as this is a first step toward implementing and evaluating strategies for personalized medicine.

AB - The promise of "personalized medicine" guided by an understanding of each individual's genome has been fostered by increasingly powerful and economical methods to acquire clinically relevant information. We describe the operational implementation of prospective genotyping linked to an advanced clinical decision-support system to guide individualized health care in a large academic health center. This approach to personalized medicine entails engagement between patient and health-care provider, identification of relevant genetic variations for implementation, assay reliability, point-of-care decision support, and necessary institutional investments. In one year, approximately 3,000 patients, most of whom were scheduled for cardiac catheterization, were genotyped on a multiplexed platform that included genotyping for CYP2C19 variants that modulate response to the widely used antiplatelet drug clopidogrel. These data are deposited into the electronic medical record (EMR), and point-of-care decision support is deployed when clopidogrel is prescribed for those with variant genotypes. The establishment of programs such as this is a first step toward implementing and evaluating strategies for personalized medicine.

UR - http://www.scopus.com/inward/record.url?scp=84862620703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862620703&partnerID=8YFLogxK

U2 - 10.1038/clpt.2011.371

DO - 10.1038/clpt.2011.371

M3 - Article

VL - 92

SP - 87

EP - 95

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 1

ER -